Abivax S.A. (ABVX) stock
ABVXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as AAVXF
$83.83+1.73 (+2.11%)
Close on Nov 18, 2026Market cap $6.58BP/E –Yield –
Abivax free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Abivax's free cash flow for the twelve months ending Jun 30, 2026 was -€197.27M. For fiscal 2025 it was -€161.27M. The highest annual figure on record is -€45.10M in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€161.27M | – |
| FY2024 | Dec 31, 2024 | -€154.71M | – |
| FY2023 | Dec 31, 2023 | -€97.40M | – |
| FY2022 | Dec 31, 2022 | -€54.22M | – |
| FY2021 | Dec 31, 2021 | -€45.10M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -€52.10M | – |
| Q1 FY2026 | Mar 31, 2026 | -€50.57M | – |
| Q4 FY2025 | Dec 31, 2025 | -€23.32M | – |
| Q3 FY2025 | Sep 30, 2025 | -€71.28M | – |
| Q2 FY2025 | Jun 30, 2025 | -€33.36M | – |
| Q1 FY2025 | Mar 31, 2025 | -€33.32M | – |
| Q4 FY2024 | Dec 31, 2024 | -€33.61M | – |
| Q3 FY2024 | Sep 30, 2024 | -€35.69M | – |
| Q2 FY2024 | Jun 30, 2024 | -€50.65M | – |
| Q1 FY2024 | Mar 31, 2024 | -€34.77M | – |
See a number that looks wrong?